Genital Infiltrations of CD4\(^+\) and CD8\(^+\) T Lymphocytes, IgA\(^+\) and IgG\(^+\) Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Chlamydia trachomatis Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01

Erneholm, Karin; Lorenzen, Emma; Boje, Sarah; Olsen, Anja Weinreich; Jungersen, Gregers; Jensen, Henrik E.; Cassidy, Joseph P.; Andersen, Peter; Agerholm, Jørgen S.; Follmann, Frank

Published in: Frontiers in Microbiology

Link to article, DOI: 10.3389/fmicb.2019.00197

Publication date: 2019

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
Erneholm, K., Lorenzen, E., Boje, S., Olsen, A. W., Jungersen, G., Jensen, H. E., Cassidy, J. P., Andersen, P., Agerholm, J. S., & Follmann, F. (2019). Genital Infiltrations of CD4\(^+\) and CD8\(^+\) T Lymphocytes, IgA\(^+\) and IgG\(^+\) Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Chlamydia trachomatis Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01. Frontiers in Microbiology, 10, [197]. https://doi.org/10.3389/fmicb.2019.00197

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Genital Infiltrations of CD4$^+$ and CD8$^+$ T Lymphocytes, IgA$^+$ and IgG$^+$ Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Chlamydia trachomatis Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01

Karin Erneholm$^{1,2,4*}$, Emma Lorenzen$^{1,2}$, Sarah Bøje$^{1,2}$, Anja Weinreich Olsen$^2$, Gregers Jungersen$^3$, Henrik E. Jensen$^4$, Joseph P. Cassidy$^5$, Peter Andersen$^2$, Jørgen S. Agerholm$^1$ and Frank Follmann$^2$

1 Section of Veterinary Reproduction and Obstetrics, Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark, 2 Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark, 3 Department of Health Technology, Technical University of Denmark, Lyngby, Denmark, 4 Section of Experimental Animal Models, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark, 5 Pathobiology Section, School of Veterinary Medicine, University College Dublin, Dublin, Ireland

The development of a vaccine against genital chlamydia in women is advancing, and the evaluation of in situ immune responses following vaccination and challenge infections is crucial for development of a safe and protective vaccine. This study employs the sexually mature minipig model to characterize the genital in situ immune response to Chlamydia trachomatis infection in pigs previously immunized intramuscularly with UV-inactivated C. trachomatis serovar D (UV-SvD) adjuvanted/formulated with CAF01 adjuvant compared to a CAF01-alone control group. Pigs immunized with UV-SvD were significantly protected against vaginal challenge with C. trachomatis on day 3 post inoculation and showed significantly higher cervical infiltrations of approximately equal numbers of CD4$^+$ and CD8$^+$ T-cells, and IgG$^+$ and IgA$^+$ plasma cells compared to adjuvant-alone immunized controls. These immunological signatures correspond to findings in mice and are similar to those described in female chlamydia patients. This proves important potential for the pig model in elucidating immunological in situ signatures in future translational research in chlamydia vaccinology.

Keywords: porcine, chlamydia, pathology, histology, vaccine
INTRODUCTION

Chlamydia trachomatis is one of the most common sexually transmitted bacteria in the world, causing infertility due to development of chronic lesions in the upper genital tract (Haggerty et al., 2010). Research into its pathogenesis and to identify preventive strategies has been ongoing for many years, primarily in murine and guinea pig models (Rank and Whittum-Hudson, 1994; Maxion et al., 2004; O’Meara et al., 2014). However, while murine models in several aspects are very useful, mice have important differences in their immune system compared to humans making interpretation of immunogenicity and pathophysiology challenging (Meurens et al., 2012; De Clercq et al., 2013; Lorenzen et al., 2015b). Nonhuman primates (NHPs) are in general more comparable to humans than mice and have been used in immunogenicity studies with C. trachomatis serotypes. However, working with NHPs is associated with high costs and ethical restrictions (Bell et al., 2011; De Clercq et al., 2013). Pigs are increasingly being used for biomedical research, as their size, anatomy, physiology and immunology in many ways are comparable to those of humans (Fairbairn et al., 2011; Dawson, 2012; Meurens et al., 2012; Lorenzen et al., 2015b; Käser et al., 2017). Prepubertal pigs have previously been used to study genital chlamydial infection (Vanrompay et al., 2005; Schautteet et al., 2011b). However, the genital tracts of prepubertal and sexually mature pigs differ in size, epithelial thickness, vascularization, immune cell infiltration and hormone fluctuations (Dyck and Swierstra, 1983; Hickey et al., 2011; Lorenzen et al., 2015b, 2016) and the use of sexually mature pigs as models should replicate events occurring in women more closely.

Traditionally, vaccine immunogenicity and efficacy are evaluated by systemic/mucosal immune responses through e.g., flow cytometry and enzyme-linked immunosorbent assays and the level of microorganisms and/or absence of pathology, respectively. Histopathological evaluation, however, can reveal detailed information on how the local in situ immune responses are localized and if pathological changes are present. Such responses are particularly important for diseases of the genital tract, where an exacerbated response in the oviducts can cause infertility, whereas a strong local immune reaction in the cervix might be protective (Paavonen and Eggert-Kruse, 1999; Maldonado et al., 2014). Furthermore, the formation of memory lymphocyte clusters in the genital tract is implied to be crucial for chlamydia protection (Morrison and Morrison, 2000; Johnson and Brunham, 2016; Johnson et al., 2018), adding further arguments/motivation to perform immunohistochemical (IHC) analysis on genital tract tissues when evaluating potential chlamydia vaccines.

In this study, we investigate how immunization with whole UV-inactivated C. trachomatis serovar D bacteria (UV-SvD) adjuvanted with CAF01 compared to CAF01 alone, influences the genital in situ lymphocyte response to genital C. trachomatis infection. The detailed aim of the study was to evaluate and identify potential in situ immune cell signatures that may correlate with protection against chlamydial infection in the sexually mature minipig model of genital C. trachomatis infection.

MATERIALS AND METHODS

Chlamydia trachomatis

Chlamydia trachomatis SvD (Trachoma type D strain UW-3/Cx, ATCC VR-885TM) was propagated in HeLa cells, harvested and purified essentially as previously described (Olsen et al., 2006). Inactivation of bacteria was achieved by exposing the bacterial solution to UV light at a distance of 5 cm for 3 h (Lu et al., 2002) and verification of the inactivation of infectivity was performed by inoculating the bacterial suspension onto McCoy cells and confirming the absence of inclusion forming units (IFU). The total protein content of the inactivated bacterial suspension was quantified by the bicinchoninic acid (BCA) method, as described in the Micro BCA™ Protein Assay Kit (cat no 23235, Thermo Scientific) and used to adjust the concentration of the bacterial suspension for intramuscular immunization.

Adjuvant and Vaccine Preparation

The adjuvant CAF01, a cationic liposome-based adjuvant, consisting of 500 μg glycolipid trehalose 6,6’-dibenenate (TDB) and 2500 μg dimethyldioctadecylammonium bromide (DDA), was prepared as described elsewhere (Hansen et al., 2008). UV-SvD bacteria were diluted in Tris-buffer (10 mM, pH 7.4) and mixed with the adjuvant (1:1), using sterile procedures.

Experimental Animals

Sexually mature, 5–6 months-old female specific pathogen free Göttingen minipigs (Ellegaard Minipigs, Soro, Denmark) were housed in the laboratory animal facilities at the Faculty of Health and Medical Sciences, University of Copenhagen, in groups of a maximum of five animals, were fed twice daily with standard minipig diet and had access to water ad libitum. Some of the pigs also served as control animals in another study (Boje et al., 2015).

Immunization, Infection Challenge and Sampling in vivo

The study was performed as two separate experiments due to logistics, with 4–5 pigs/group in each experiment. The pigs were intramuscularly immunized with 125 ug UV-SvD in CAF01 adjuvant (UV-SvD/CAF01) (n = 8) or with the adjuvant alone, (CAF01) (n = 9), as a control group, twice with an interval of 2–3 weeks (Table 1). Following the immunization the pigs were estrus synchronized with Regumate Equine® (MSD Animal Health, Ballerup, Denmark) and 3–4 weeks after the last immunization, the animals were anesthetized during estrus with a Zoletil® 50 mixture as described by Lorenzen et al., (2015a), and inoculated deep intravaginally with 4 × 10⁸ IFU C. trachomatis SvD in 5 ml 250 mmol/l sucrose, 10 mmol/l NaH₂PO₄, and 5 mmol/l L-glutamic acid (SPG) using an insemination catheter (Osrís, E-vet, Denmark). The rear aspect of each inoculated pig was slightly elevated for 20 min post inoculation (pi) to reduce reflux of inoculum.
The pigs were clinically monitored and had their rectal temperature taken every second day in the post inoculation period: animals with body temperatures exceeding 39.5°C were considered pyrexic. Any changes in behavior, appetite, urination, defection, vulval appearance or vaginal discharge were recorded.

Vaginal swabs were taken prior to inoculation and at euthanasia (week 2 pi) to monitor the level of mucosal antibodies and presence of C. trachomatis in the pi period. For antigen detection, additional vaginal swabs were taken on day 3 pi and week 1 pi as well. The swabs were immediately placed in 1 ml SPG and kept on ice until further handling. Three glass beads were added to each sample tube, and the samples were whirl mixed for 1 min, where after the swab material was aliquoted and stored at -80°C until further analysis. Blood samples were taken prior to inoculation and at 2 weeks pi, from the jugular vein in heparin-stabilized tubes for cell isolation and plain tubes for serum isolation. The plain tubes were centrifuged for 15 min at 2400 g, and serum was isolated and kept at −20°C until further handling.

q-PCR Detection of C. trachomatis
The vaginal swabs for q-PCR detection were treated slightly differently in the two separate experiments, however, all samples from day 3 pi were treated similarly: DNA extraction was performed with Chelex®100 (Bio-Rad, Life Science, Denmark) and real-time q-PCR detection of C. trachomatis was performed by detection of the 16S rRNA gene as described in (Boje et al., 2015; Ernehom et al., 2016). Based on the negative control, the Ct cut-off for true positive samples was determined to be 37.

Measurement of C. trachomatis Specific Antibodies in Serum and in Vaginal Swabs
Determination of antigen-specific antibodies in serum and vaginal swabs was carried out using an indirect ELISA coating with UV-inactivated C. trachomatis SvD (4 µg/ml) as described previously (Ernehom et al., 2016). Confirmed positive serum from a previous study was included as a positive control and used as an internal standard to correct for plate-to-plate variation. Results are presented as corrected OD values, calculated as the increase in OD-value on day 14 pi compared to day 0 pi (corrected OD_{day14pi} = OD_{day14pi} – OD_{day 0pi}).
The frozen tissues were cut on a cryostat, fixed in ice cold acetone for 20 min and air dried. The sections were kept at –20°C until further handling.

**Histochemical and Immunohistochemical Staining**

Representative histosections were selected for visualization of plasma cells, T cells and T cell subsets. For visualization of plasma cells, the slides were incubated in methyl green pyronin solution (MGP) (Sigma-Aldrich) for 10 min, rinsed in distilled water, and air dried and mounted in xylene.

For visualization of T cells (CD3+), helper T cells (CD4+), and cytolytic T cells (CD8+), as well as isotype-specific plasma cells through membrane-bound IgA and IgG, immunohistochemistry was performed, see Table 2 for details. The anti-CD8 antibody used binds the b epitope of the CD8α chain. In pigs, CD8α is constitutively expressed on cytolytic T cells and expressed upon antigen activation of CD4 and γδ T cells (Gerner et al., 2009). Blocking and incubation steps were performed according to the manufacturers’ recommendations. A negative control was included using a non-sense antibody (goat serum for IgA and IgG, isotype specific IgG for CD3 (mouse IgG1, Clone P3.6.2.8.1, eBioscience), CD4 (mouse IgG2b, clone MPC-11, BD Pharmingen) and CD8 (mouse IgG2a, clone C1.18.4, BD Pharmingen). In addition, positive control sections were included. The complete list of antibodies used for IHC is included in Table 2.

**Statistics**

Statistical analyses were carried out using Graph Pad Prism 5. The Mann-Whitney test was used to analyze differences between the groups. P < 0.05 was considered statistically significant. The following symbols were used to designate significance: *P 0.01 to 0.05, **P 0.01–0.001, ***P < 0.001.

**Ethics Statement**

This study was carried out in accordance with the recommendations of the EU Directive 2010/63, Danish Animal Experiments Inspectorate of the Danish Veterinary and Food Administration. The protocol was approved by the Danish Animal Experiments Inspectorate with license no: 2008/561-1581.

| Target antigen       | Manufacturer             | Dilution and incubation of primary antibody | Detection method and chromogen |
|----------------------|--------------------------|---------------------------------------------|-------------------------------|
| Formalin fixed tissue|                          |                                             |                               |
| Mouse anti-pig CD3   | Southern Biotech Clone PPT3 | 1:1000 o/n 4 °C                            | Ultravision One DAB®          |
| Goat anti-pig IgA    | Nordic Biosite Lot no: A100-102A-16 | 1:4000 1 h RT                             | Vectastain Elite-ABC – Goat AEC® |
| Goat anti-pig IgG    | Nordic Biosite Lot no: A100-104A-12 | 1: 7000 1 h RT                           | Vectastain Elite-ABC – Goat AEC® |
| Frozen tissue        |                          |                                             |                               |
| Mouse anti-pig CD4   | Southern Biotech Clone 74-12-4 | 1:500 1 h RT                          | Ultravision AEC               |
| Mouse anti-pig CD8α  | BD Pharmingen Clone 295/33-25 | 1:500 1 h RT                          | Ultravision AEC               |

All formalin fixed tissue was exposed to antigen retrieval by microwave boiling in ¹TEG buffer pH 9.0 for 2 × 5 min, ²Citrate buffer pH 6.0 for 5 min, and blocked for endogenous peroxidase in a solution of hydrogen peroxide (0.6%) for 15 min. RT = room temperature.

**RESULTS**

**Chlamydia trachomatis Infectious Load Following Inoculation**

Pigs were intramuscularly immunized with 125 µg UV-SvD in CAF01 (UV-SvD/CAF01) (n = 8) and the control group was administered adjuvant alone (CAF01) (n = 9) by the intramuscular route. The animals were challenged during estrus by deep vaginal inoculation with 4 × 10⁸ IFU C. trachomatis SvD and all pigs remained clinically unaffected throughout the study. Following vaginal challenge, infectious load was determined in vaginal swabs by q-PCR, detecting C. trachomatis 16S RNA genes. The immunization with UV-SvD/CAF01 induced protection in terms of a significantly lower vaginal bacterial load on day 3 pi in the UV-SvD/CAF01 group, compared to the control/CAF01 group (Figure 1). On the next sampling day (i.e., day 7 pi), only 2 out of 9 animals in the CAF01 group and 1 out of 8 animals in the UV-SvD/CAF01 group had detectable levels of vaginal C. trachomatis by q-PCR. On the following sampling (days 12 or 14 pi) 1 out of 9 animals in the CAF01 group and 2 animals in the UV-SvD/CAF01 group had detectable levels of vaginal C. trachomatis (Supplementary 1).

![Figure 1](https://example.com/figure1.png)
**Necropsy and Histopathological Examination of the Genital Tract**

At necropsy, congestion was observed in the broad ligament of the uterus in pigs of both groups. In all animals, the uterine mucosa was edematous and slightly congested, and the ileosacral lymphocentrum was slightly enlarged. Pigs in the UV-SvD/CAF01 group had significantly greater infiltration of lymphocytes in the mucosa of the uterus ($p = 0.0021$), cervix ($p = 0.0002$), and vagina ($p = 0.01$) relative to the CAF01 group (Figures 2C,F). The lymphocytes were typically observed in moderate numbers, localized subepithelially, either scattered in the stroma, or aggregated in follicles (Figure 2). In the UV-SvD/CAF01 group, the lymphocytes were also located perivascularly in the mucosa (Figure 2B, arrow). Intraepithelial lymphocytes were found to a lesser extent in both groups (Figure 2E, arrowheads). A significantly denser infiltration of plasma cells was present in the cervix of the UV-SvD/CAF01 group, compared to the control group (Figure 2E insert, and Supplementary 2). The plasma cells were typically located in subepithelial clusters, intermingled with lymphocytes, and diffusely scattered in the subepithelial stroma. Neutrophils were noted in low numbers in the epithelium and subepithelial stroma of the vagina and cervix, in both groups (Figures 2A–E). Mild to moderate hydrotic degeneration and cytoplasmic vacuolation, was a feature of the vaginal and cervical epithelium of both groups (Figure 2E, arrowheads), with accompanying mild to moderate intraepithelial microabcessation. The severity of epithelial degeneration was slightly greater in the cervix than in the vagina in both groups; however, no differences were found between the two groups. Lesions were not found in the oviducts of either groups.

**Characterization of Leukocyte Infiltration**

To further analyze the leukocyte infiltration in the lower genital tract, representative sections were selected and stained immunohistochemically with anti-CD3 for detection of T cells, and with MGP to confirm the presence of plasma cells. As visualized in Figure 3, the cell accumulations in the stroma were to a large extent made up of CD3$^+$ cells. As visualized in Figures 2C,F,I). The lymphocytes were typically observed in moderate numbers, localized subepithelially, either scattered in the stroma, or aggregated in follicles (Figure 2). In the UV-SvD/CAF01 group, the lymphocytes were also located perivascularly in the mucosa (Figure 2B, arrow). Intraepithelial lymphocytes were found to a lesser extent in both groups (Figure 2E, arrowheads). A significantly denser infiltration of plasma cells was present in the cervix of the UV-SvD/CAF01 group, compared to the control group (Figure 2E insert, and Supplementary 2). The plasma cells were typically located in subepithelial clusters, intermingled with lymphocytes, and diffusely scattered in the subepithelial stroma. Neutrophils were noted in low numbers in the epithelium and subepithelial stroma of the vagina and cervix, in both groups (Figures 2A–E). Mild to moderate hydrotic degeneration and cytoplasmic vacuolation, was a feature of the vaginal and cervical epithelium of both groups (Figure 2E, arrowheads), with accompanying mild to moderate intraepithelial microabcessation. The severity of epithelial degeneration was slightly greater in the cervix than in the vagina in both groups; however, no differences were found between the two groups. Lesions were not found in the oviducts of either groups.

**Chlamydia trachomatis Specific Immune Responses Following Inoculation**

The UV-SvD/CAF01 immunized pigs had significantly higher *Chlamydia*-specific IgG levels in serum on the day of infection (0 pi) ($p = 0.0138$) and on day 14 pi ($p = 0.0291$), compared to the CAF01 group (Supplementary 4). Furthermore, the UV-SvD/CAF01 immunized pigs had significantly higher *Chlamydia*-specific IgG levels on the vaginal surface on day 14 pi compared to the CAF01 control group ($p = 0.0286$, Figure 4F) and similarly these animals exhibited a significantly higher systemic IFN-γ response from re-stimulated PBMCs on day 14 pi ($p = 0.0079$). In addition, the UV-SvD/CAF01 group also showed significantly higher IFN-γ responses in cells from the re-stimulated iliosacral lymph node at day 14 pi ($p = 0.0015$).

**DISCUSSION**

The essential aim of this study was to evaluate and identify potential *in situ* immune cell signatures that may correlate with protection against chlamydial infection in the sexually mature minipig model of genital *C. trachomatis* infection. The genital *in situ* immune cell signature in the UV-SvD/CAF01 vaccinated group, associated with the significant protection on day 3 pi in this group, consisted of significant infiltrations of plasma cells and T cells in the sub-epithelial stroma of the lower genital tract, particularly in the cervical stroma. The immune cells were present in a scattered distribution as well as in sub-epithelial lymphoid follicles consisting of approximate equal numbers of CD4$^+$ and CD8$^+$ T cells, along with IgG$^+$ and IgA$^+$ plasma cells. While it is not a given that these immune cells are *C. trachomatis*-specific, the IHC results correlate well with the significant *C. trachomatis*-specific IFN-γ,
FIGURE 2 | Histopathological changes including lymphocyte counts in the minipig vagina, cervix and uterus. The first and second column show representative pictures from the CAF01 and the UV-SvD/CAF01 groups, respectively. Each row represents the different anatomical locations: the vagina, cervix and uterus. The scale bar equals 200 µm. (A) In the vagina of the CAF01-group, there is a low number of lymphocytes scattered in the subepithelial stroma. (B) UV-SvD/CAF01 group, vagina. A profound perivascular infiltration of lymphocytes is noted (arrow), and also a subepithelial diffuse infiltration of lymphocytes (arrowheads). Blood vessel marked with asterisk (*). (C) Comparison of the semiquantitative lymphocyte infiltration scores, showing a significant difference in the lymphocyte score in the vagina of the two groups. Each dot represents one animal. Bars show median. (D) CAF01-group, cervical tissue, where a small subepithelial lymphocyte infiltration is extending into the epithelium (arrow). (E) In the cervix of the UV-SvD/CAF01 group, there is a dense subepithelial infiltration of lymphocytes (arrow) and plasma cells (insert, arrow). Intraepithelial vacuoles (arrowheads) and lymphocytes are also noted. (F) Comparison of the semiquantitative lymphocyte infiltration scores, showing a highly significant difference in the lymphocyte score in the cervix of the two groups. Each dot represents one animal. Bars show median. (G) In the uterus, stromal edema is found in the CAF01-group. (H) In addition to stromal edema, multiple small perivascular lymphocytic accumulations (arrowheads) are seen in the UV-SvD/CAF01 group. Blood vessel marked with asterisk (*). (I) Comparison of the semiquantitative lymphocyte infiltration scores, showing a significant difference in the lymphocyte score in the uterus of the two groups. Each dot represents one uterine horn. Bars show median. Statistics: Mann-Whitney test. Asterisks (*) indicate the level of significance: *P < 0.05, **P < 0.01–0.001, and ***P < 0.001.

IgG and IgA responses (Figures 3, 4) suggesting that the IHC data represent an in situ C. trachomatis-specific response.

The increased numbers of CD8+ T cells in the genital tract is consistent with previously described resident CD8+ cells in the porcine uterine epithelium (Kaeket et al., 2001, 2002), which are analogous to intraepithelial T cells in human cervical epithelium (Johansson et al., 1999). Likewise, a larger proportion of CD8+ cells have been found in infected NHPs (Van Voorhis et al., 1996) and guinea pigs (Rank et al., 2000), whereas in mice, CD4+ T cells have been found to dominate following vaccination and Chlamydia challenge (Morrison and Morrison, 2000; Johansson and Lycke, 2001). Importantly, the composition of the cellular infiltrate in the pig model is similar to that reported in human cases of chlamydial cervicitis, including subepithelial inflammation with increased numbers of both CD4+ and CD8+ T cells, plasma cells and lymphoid follicle formation (Kiviat et al., 1990; Mittal et al., 2004; Ficarra et al., 2008; Agrawal et al., 2009). Hence, immunized pigs may mount an adaptive immune response in situ mimicking reinfection in human patients with chlamydial cervicitis. It should be noted that the anti-CD8 antibody used does not differentiate CD8+ single positive cytolytic T cells and antigen-activated CD8+/CD4+ double positive helper T cells. In pigs 10–13% of the T cells can be CD8+/CD4+ double positive, hence a proportion of the identified CD8+
FIGURE 3 | CD3, CD4, and CD8 T cells in the cervix along with C. trachomatis specific PBMC IFN-γ responses. Representative sections from the cervix were immunohistochemically (IHC) stained against CD3, CD4, and CD8α. All pictures and graphs are from day 14 pi. The left column shows the adjuvant (CAF01) control group IHC stains, the middle column shows the UV-SvD/CAF01 IHC stains and the right column presents C. trachomatis specific immune responses in PBMCs (G) and lymph nodes (H). CD3 (A,B): CD3+ cells (brown) were detected in all sections. (A) In the CAF01-group the CD3+ cells were mainly located intraepithelially (arrows). (B) In the UV-SvD/CAF01 group, the CD3+ cells were typically accumulated in the subepithelial stroma (encircled), and occasionally also intraepithelially (arrow). CD4 (C,D): CD4+ cells (staining red) were found in both groups, localized in subepithelial lymphoid accumulations (D, arrow), and occasionally in the epithelium; however, to a larger degree in the UV-SvD/CAF01 group (D). CD8+ cells were found both intraepithelially and subepithelially in both groups (arrows), with a larger amount in the UV-SvD/CAF01 group, in a similar fashion to the CD4+ cells. In lymphoid accumulations, primarily present in the UV-SvD/CAF01 group, the density of CD4+ and CD8+ cells were approximately equal (also illustrated in supplementary 3). The right column shows C. trachomatis specific immune responses. Each dot represents one animal. The gray bar shows the median (G) system T-cell response: IFN-γ response from PBMCs re-stimulated with C. trachomatis (H) T-cell response in the uterine draining lymph node: IFN-γ response from lymph node cells re-stimulated with C. trachomatis Statistics: Mann-Whitney test. Asterisks (*) indicate the level of significance: *P 0.01 to 0.05, **P 0.01–0.001, and ***P < 0.001.

cells might be double positive (Gerner et al., 2009, 2015). However, when comparing the distribution of CD4+ and CD8+ positive cells (Supplementary 3) it is clear that the intraepithelial T cells are predominantly CD8+ single positive cytolytic T cells.

The finding of IgA+ and IgG+ plasma cells in the genital tract following vaginal challenge upon intramuscular immunizations is promising from the perspective of an intramuscular immunization strategy, but contradicts to some extent recent studies indicating that a mucosal/intranasal booster immunization is needed to trigger significant IgA (Lorenzen et al., 2015a; Christensen et al., 2017) and T cell responses on the genital mucosa (Stary et al., 2015). However, other studies in pigs have also shown protection without the addition of a mucosal booster (Schautteet et al., 2011a; Bøje et al., 2015). Clearly, the route of administration influences the immune response (Rank et al., 1990; Lu et al., 2002; Stary et al., 2015) and for both mucosal as well as parenteral immunizations it is important to use the optimal adjuvant/delivery system to direct the appropriate immune response (Igietseme et al., 2011; Stary et al., 2015). In a comparative study of five clinically tested adjuvants for parenteral use (IC31®, CAF01, GLA-SE, MF59® and Alum), Knudsen et al., 2016 demonstrated that CAF01 has an immunological profile (Th1/Th17) tailored for Chlamydia. Similarly, parenteral immunization with UV-EBs formulated in the (Th1) AS01B adjuvant can elicit significant protection (Coler et al., 2009). Future studies are required to elucidate the effect of immunization routes/adjuvants and the relative impact of effector T cells, genital IgA producing plasma cells and vaginal IgG on bacterial clearance. In such studies, the immune cell subsets could also be quantified.

An important perspective of evaluating in situ responses and cell signatures is to be able to distinguish between protective and aberrant cell mediated responses that cause oviduct pathology (Paavonen and Eggert-Kruse, 1999; Maldonado et al., 2014).
In general, the vagina and especially the cervix function as immune-inductive sites, with formation of mucosa-associated lymphoid aggregates in response to local antigenic stimulation (Pudney et al., 2005). This is normally a non-pathologic response, protecting the genital tract from ascending infections (Pudney et al., 2005). Tissue-resident T cells are crucial for protective immunity in the genital tract, both against *Chlamydia* (Igietseme and Rank, 1991; Johansson and Lycke, 2001; Olive et al., 2011), and herpes simplex virus 2 (Iijima and Iwasaki, 2014). In fact it has recently been hypothesized that the establishment of *C. trachomatis*-specific memory lymphocyte clusters in the genital mucosa is crucial for protection against chlamydial infection (Stary et al., 2015; Johnson and Brunham, 2016). Furthermore, the development of tertiary lymphoid tissue at sites of inflammation has also been associated with increased protection at other anatomical locations exposed to microorganisms from the external environment (Wiley et al., 2009).

In the current study, few histopathological changes were observed in the uterine horns, and no lesions were found in the oviducts. It is likely that the bacteria did not ascend to the upper genital tract during this study, due to the short duration of infection and long and complex nature of the porcine cervix as discussed in (Lorenzen et al., 2015b). For true evaluation of upper genital tract cell signatures and development of pathology, the model should be optimized e.g., by inoculating directly into the uterus as recently performed (Lorenzen et al., 2017). Nonetheless, the observed inflammation in the porcine cervix is similar to what occurs in human chlamydial cervicitis, representing most of the human infections (Brunham and Rey-Ladino, 2005). Only a small percentage of asymptomatic cervical chlamydial infections are actually estimated to ascend the genital tract (Haggerty et al., 2010).

The systemic immune response was also evaluated in the present study, and the robust *Chlamydia*-specific antibody and IFN-γ responses in the UV-SvD/CAF01 vaccinated animals were consistent with previous studies with CAF01 (Agger et al., 2008) and are also similar to responses to immunization with UV-inactivated *Chlamydia* in guinea pigs (Rank et al., 1990) and mice (Lu et al., 2002).

**CONCLUSION**

In conclusion, the significant protection of minipigs immunized with UV-SvD/CAF01 was associated with significant infiltrations of CD4⁺ and CD8⁺ T lymphocytes and IgA⁺ and IgG⁺ plasma cells to the lower genital tract with the attendant formation of intra-mucosal lymphoid follicles. These findings correspond to the “immune cell signatures” that develop during chlamydial cervicitis in women and highlight the potential use of this experimental infection model for more detailed evaluation of *in situ* responses during vaccine trials including its use in distinguishing pathologic from protective responses.
FUNDING

The work was supported by Aase og Ejnar Danielsen’s Foundation, Innovation Fund Denmark through the project GeniVac [069-2011-1] and by the Faculty of Health and Medical Sciences, University of Copenhagen.

ACKNOWLEDGMENTS

We wish to thank Jørgen Skov Jensen and Maria Rathmann Sørensen for help with q-PCR analyses, and the laboratory technicians Betina Gjedsted Andersen, Elisabeth Petersen, Anne Dorte Roed, and Heidi Elise Holm for assistance in the experiments and preparation of histological sections.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2019.00197/full#supplementary-material
Johnson, R. M., Yu, H., Strank, N. O., Karunakaran, K., Zhu, Y., and Bruhnam, R. C. (2018). B cell presentation of Chlamydia antigen selects out protective CD4+ T Cells: implications for genital tract tissue-resident memory lymphocyte clusters. *Infect. Immun.* 86:e00614-17. doi: 10.1128/IAI.00614-17

KaeoKet, K., Dalin, A. M., Magassou, U., and Persson, E. (2001). The sow endometrium at different stages of the oestrous cycle: studies on the distribution of CD2, CD4, CD8 and MHC class II expressing cells. *Anim. Reprod. Sci.* 68, 99–109. doi: 10.1016/S0378-4320(01)00142-7

KaeoKet, K., Persson, E., and Dalin, A.-M. (2002). Corrigendum to “The sow endometrium at different stages of the oestrous cycle: studies on morphological changes and infiltration by cells of the immune system” [Anim. Reprod. Sci. 65 (2001) 95–114]. *Anim. Reprod. Sci.* 73, 89–107. doi: 10.1016/S0378-4320(02)00126-4

Käser, T., Renois, F., Wilson, H. L., Crudde, T., Gerdis, V., Dillon, J. A. R., et al. (2017). Contribution of the swine model in the study of human sexually transmitted infections. *Infect. Genet. Evol.* 66, 346–360. doi: 10.1016/j.meegid.2017.11.022

Kviat, N. B., Paavonen, J. A., Wolner-Hanssen, P., Critchlow, C. W., Stamm, W. E., Douglas, J., et al. (1990). Histopathology of endometrial infection caused by *Chlamydia trachomatis*, herpes simplex virus, *Trichomonas vaginalis*, and *Neisseria gonorrhoeae*. *Hum. Pathol.* 21, 831–837. doi: 10.1016/0146-8177(90)90052-J

Knudsen, N. P. H., Olsen, A., Buonsanti, C., Follmann, F., Zhang, Y., Coler, R. N., et al. (2016). Different human vaccine adjudants promote distinct antigen-independent immunological signatures tailored to different pathogens. *Sci. Rep.* 6:19570. doi: 10.1038/srep19570

Lorenzen, E., Agerholm, J. S., Grossi, A. B., Bojesen, A. M., Skytte, C., Erneholm, K., et al. (2016). Characterization of cytological changes, IgA, IgG and IL-8 levels and pH value in the vagina of prepubertal and sexually mature female Göttingen minipigs during an estrous cycle. *Dev. Comp. Immunol.* 59, 57–62. doi:10.1016/j.devimm.2016.01.006

Lorenzen, E., Follmann, F., Boje, S., Erneholm, K., Olsen, A. W., Agerholm, J. S., et al. (2015a). Intramuscular priming and intranasal boosting induce strong waves of protective memory T cells. *Science* 348:aaa8265. doi: 10.1126/science.aaa8205

Van Voorhis, W. C., Barrett, L. K., Sweeney, Y. T., Kuo, C. C., and Patton, D. L. (1996). Analysis of lymphocyte phenotype and cytokine activity in the inflammatory infiltrates of the upper genital tract of female macaques infected with *Chlamydia trachomatis*. *J. Infect. Dis.* 174, 647–650. doi: 10.1093/infdis/174.3.647

Vanrompay, D., Hoang, T. Q. T., De Vos, L., Vermimmen, K., Harkinezhad, T., Chiers, K., et al. (2005). Specific-pathogen-free pigs as an animal model for studying *Chlamydia trachomatis* genital infection. *Infect. Immun.* 73, 8317–8321. doi: 10.1128/IAI.73.12.8317-8321.2005

Wiley, J. A., Richert, L. E., Swain, S. D., Harmsen, A., Barnard, D. L., Randall, T. D., et al. (2009). Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. *PLoS One* 4:e7142. doi: 10.1371/journal.pone.0007142

Conflict of Interest Statement: PA is co-inventor on an issued patent (US8727825) covering the use of CAFO as vaccine adjuvant. All rights have been assigned to Statens Serum Institut, a Danish not-for-profit governmental institute.

The handling Editor declared a past supervisory role with the author KE.

Copyright © 2019 Erneholm, Lorenzen, Boje, Olsen, Jungersen, Jensen, Cassidy, Andersen, Agerholm and Follmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.